Vesugen Research Overview (also known as Kidney peptide bioregulator, Khavinson kidney peptide, Vesugen Ala-Glu-Asp-Arg)
A peptide studied for vascular wall integrity support, microcirculation improvement, and vascular healing. Research interest includes varicocele models and vascular resilience applications. Often combined with Ventfort in circulation-focused research.
What Is Vesugen?
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson specifically targeting vascular endothelial tissue. It is a fully synthetic peptide with high specificity for endothelial cells, designed to restore normal vascular cell gene expression and support angiogenesis — the formation of new blood vessels — in aging or ischemia-damaged tissue. It complements Ventfort's broader vascular coverage by focusing on endothelial cell biology specifically.
Endothelial-Specific Focus
The endothelium — the single cell layer lining all blood vessels — regulates vascular tone through nitric oxide and prostacyclin production, maintains anticoagulant properties of the vessel wall, mediates inflammatory cell recruitment, and governs angiogenesis through VEGF and angiopoietin signaling. Vesugen is designed to restore normal endothelial cell gene expression across all these functions.
Research Applications
Vesugen has been studied for peripheral vascular disease, ischemic heart disease, wound healing in the context of poor vascularity, and as an anti-aging vascular restoration agent. Animal studies document increased endothelial cell density in ischemic tissue, improved capillary density, enhanced eNOS expression and nitric oxide production, and faster recovery of blood flow following ischemic challenge in treated animals. Russian clinical research documents improvements in peripheral vascular function and microcirculation in elderly patients.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C. Reconstituted: 2–8°C, use within 7–10 days |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
Research Indications
Cardiovascular
Vascular Endothelial Aging
Ki-67 stimulation in aged endothelial cell cultures (preclinical only).
Atherosclerosis Models
E-selectin reduction and SIRT1 upregulation in vascular cells and rat models (preclinical).
Anti-Aging
Stem Cell Senescence
p16 / p21 reduction in human PDLSC and GMSC stem cell cultures.
Neuroprotection
5xFAD Mouse Alzheimer Model (with correction)
Dendritic spine preservation reported in PMID 34071923; source paper has January 2025 correction.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Vascular aging / circulation (RUO inj.) | 0.5–2 mg | Once daily | SubQ |
| Vascular / cardiovascular support (oral) | 10–20 mg (1–2 caps) | 1–2× daily · 1 month | Oral |
| Cerebral circulation / cognitive (oral) | 10–20 mg (1–2 caps) | 1–2× daily · repeated | Oral |
| Sublingual vascular support | ~10 mg (5–6 drops) | 3–4× daily · 1 month | Sublingual |
Timing
No measured Cmax / Tmax / half-life published. Class half-life estimated at ~15 min serum. Functional vascular and neurovascular effects build over 10–30-day courses and are believed to persist for months after dosing stops.
Peptide Interactions
Both are Khavinson-developed bioregulators targeting different tissue axes (Epitalon = pineal/telomerase; Vesugen = vascular). Co-administration is part of the Khavinson gerontology protocol framework, though no peer-reviewed interaction study has been published.
Pinealon (Glu-Asp-Arg) and Vesugen are commonly stacked in Khavinson short-peptide protocols targeting neurovascular aging. The 2015 elderly polymorbidity observational study (PMID 26390612) used Vesugen and Pinealon together but reported Vesugen as the stronger anti-aging signal.
Different tissue targets (Cartalax = cartilage/connective tissue; Vesugen = vascular endothelium). Both are short Khavinson bioregulators with overlapping epigenetic mechanisms but no documented interaction.
Both target cardiovascular tissues via different mechanisms (Cardiogen acts on cardiomyocyte apoptosis; Vesugen acts on endothelial proliferation). No published interaction data, theoretically complementary.
Vesugen modulates endothelin-1 and vascular tone markers in vitro. Theoretical interaction with calcium channel blockers, ACE inhibitors, ARBs, and PDE5 inhibitors has not been studied. Patients on antihypertensive therapy should consult a physician before use.
No published interaction data with warfarin, DOACs, or antiplatelet drugs. The vascular endothelial mechanism is theoretically downstream of coagulation, but interaction has not been formally studied.
No published data. Mechanism is local epigenetic regulation of vascular endothelial genes, not systemic immunomodulation, so interaction is theoretically minimal but not characterized.
Vilon (Lys-Glu) is a Khavinson dipeptide that shares two of the three amino acids in Vesugen and overlapping epigenetic effects. Co-administration is redundant rather than complementary based on the published mechanistic overlap.
Reported Research Timeline
01First 1–2 weeks (injectable course) (reported in cited studies): Endothelial gene expression begins to shift, with early improvements in NO-dependent vasorelaxation and microcirculation. The vasculogenic ED clinical study showed measurable improvements in penile arterial blood flow after a short Vezugen course — the earliest documented human vascular signal.
0210–30 days (full course): RUO narratives describe improved circulation, decreased vascular permeability (reduced edema and leaky-vessel symptoms), and support for blood–brain barrier integrity. Subjective improvements in blood-flow-related symptoms — cold extremities, performance, cerebral clarity — are reported over this window. Oral and sublingual courses run for 1 month with similar gradual buildup.
03Post-course (months off): Because Vesugen acts epigenetically — restoring gene-expression patterns in endothelial cells rather than forcing acute pharmacologic responses — vascular renewal capacity, NO signaling, and microcirculation improvements are thought to persist for months after the peptide clears. This supports using 2–3 short courses per year rather than continuous daily dosing.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
No structured Phase I safety study. Two small Russian observational studies (n=41 ED, n=32 polymorbidity) reported no AEs but used no formal AE protocol.
Antihypertensive, anticoagulant, and PDE5 interactions on this page are directional logic, not validated data.
Pregnancy, lactation, renal/hepatic impairment, pediatrics not studied; default to non-use in these populations.
PMID 34071923 (mouse Alzheimer) has a January 2025 published correction; corrected content not specified in the public abstract.
Sold in Russia as a BAFS dietary supplement, not as a registered pharmaceutical. Not FDA / EMA approved.
Seek Medical Attention If:
Allergic / hypersensitivity reaction
Cardiovascular symptoms (palpitations, chest pain, syncope)
Injection-site reaction beyond mild redness
Any unexpected systemic symptom
Quality Indicators
Verified Marker
White lyophilized powder, sealed vial with batch / expiry
Legitimate Vesugen appears as white to off-white powder in a sealed labeled vial.
Verified Marker
Clear reconstituted solution
Solution should be completely clear after gentle swirling.
Acceptable Range
Verify sequence is Lys-Glu-Asp (KED)
Confirm COA. Adjacent compounds (Vilon KE, Livagen KEDA, Ovagen EDL) share letters and are commonly confused.
Quality Concern
Cloudy, yellow, or particulate solution
Discard. Indicates degradation or contamination.
Research Citations
- Neuroprotective Effects of Tripeptides - Epigenetic Regulators in Mouse Model of Alzheimer's Disease
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M, 2021, Pharmaceuticals (Basel) - Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease
Khavinson V, Linkova N, Diatlova A, Trofimova S, 2021, Bulletin of Experimental Biology and Medicine - Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VKh, Dyakonov MM, Kozina LS, 2016, Advances in Gerontology - Molecular aspects of anti-atherosclerotic effects of short peptides
Khavinson VKh, Lin'kova NS, Evlashkina EV, Durnova AO, Kozlov KL, Gutop OE, 2014, Bulletin of Experimental Biology and Medicine - The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people
Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh, 2014, Advances in Gerontology - Short Peptides Protect Oral Stem Cells from Ageing
Sinjari B, Diomede F, Khavinson V, et al., 2020, Stem Cell Reviews and Reports - Peptides tissue-specifically stimulate cell differentiation during their aging
Khavinson VKh, Lin'kova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM, 2012, Bulletin of Experimental Biology and Medicine
Research Focus
Vascular health, Blood vessel restoration, Angiogenesis, Anti-aging, Endothelial function
Verified Vendors Carrying Vesugen
Frequently Asked Questions
What should researchers watch for with Vesugen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Vesugen?
First 1–2 weeks (injectable course) (reported in cited studies): Endothelial gene expression begins to shift, with early improvements in NO-dependent vasorelaxation and microcirculation. The vasculogenic ED clinical study showed measurable improvements in penile arterial blood flow after a short Vezugen course — the earliest documented human vascular signal.
How is Vesugen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →